Move beyond the guidance language to the operational judgment ICH Q14 and Q2(R2) demand — method flexibility, control strategies, post-validation changes, and the evidence needed to sustain method performance across the lifecycle.
Includes live access & recording
The implementation of ICH Q14 and the revised ICH Q2(R2) guidance is changing how organizations approach analytical method development, validation, transfer, maintenance, and lifecycle management. While many companies understand the principles described within the guidance documents, uncertainty often arises when translating those expectations into practical laboratory, quality, validation, and regulatory activities.
Questions frequently emerge around method flexibility, development documentation, analytical control strategies, post-validation changes, and the evidence needed to support ongoing method performance throughout the product lifecycle.
This session examines the operational impact of ICH Q14 and Q2(R2) beyond the guidance language itself, focusing on how analytical lifecycle concepts influence method development decisions, validation strategies, change management activities, continued performance monitoring, and regulatory expectations. Practical examples will be used to explore how organizations can apply lifecycle principles while maintaining scientific rigor, operational efficiency, and regulatory compliance.
Historically, many methods were developed, validated, approved, and then treated as static objects. The problem is that methods continue to live for years, sometimes decades. Laboratories change, analysts change, equipment changes, products evolve, investigations occur, transfers happen, and performance drifts over time. Many of the most difficult analytical decisions arise long after the original validation work has been completed.
Organizations often discover that the greatest challenge is not generating validation data, but explaining why a method was designed a certain way, determining how much flexibility exists when changes become necessary, and deciding what evidence is required to support those changes.
This session focuses on the operational and scientific judgment required to manage analytical methods throughout their lifecycle while maintaining confidence in method performance, regulatory compliance, and long-term sustainability.
Four shifts in thinking that move an organization from static, one-time validation toward true analytical lifecycle management.
Understand how ICH Q14 supports defined method flexibility and adjustment ranges — and how to establish that flexibility without creating regulatory exposure.
Build control strategies that support lifecycle management rather than a single point-in-time validation event.
Learn how to determine when a method change requires additional validation, justification, or neither — and how to document that decision defensibly.
Detect meaningful drift in ongoing method performance and manage transfer challenges across laboratories and sites.
Attendees will leave able to apply ICH Q14 and Q2(R2) lifecycle principles to real development, validation, transfer, and change-management decisions.
Determine what evidence is sufficient during analytical method development.
Establish method flexibility and adjustment ranges without creating regulatory risk.
Define analytical control strategies that support ongoing lifecycle management.
Decide when method changes require additional validation or documented justification.
Manage method transfer challenges across laboratories and sites.
Monitor ongoing method performance and detect meaningful drift over time.
Eight focused topics covering the operational expectations of ICH Q14 and Q2(R2) across the analytical method lifecycle.
Teams across analytical development, quality, laboratory operations, and regulatory affairs responsible for method lifecycle decisions.
Analytical Development Scientists
Quality Control (QC) Departments
Quality Assurance (QA) Departments
Laboratory Managers and Supervisors
Validation and Qualification Professionals
Regulatory Affairs Departments
CMC and Technical Services Personnel
Pharmaceutical & Biotechnology Manufacturing Professionals
ICH Q14 and the revised ICH Q2(R2) reframe analytical procedures as lifecycle assets rather than one-time deliverables validated once and left unchanged. The guidance introduces enhanced approaches to method development, structured analytical target profiles, defined method operable design regions, and control strategies intended to carry a method through development, validation, transfer, routine use, and change over its full life.
In practice, this shifts the burden from simply generating validation data to explaining the scientific rationale behind method design choices, defining how much flexibility a method can tolerate before a change becomes significant, and determining what evidence is required to support that change without triggering unnecessary revalidation. Laboratories, quality units, and regulatory functions must coordinate on control strategies, performance monitoring, and transfer protocols that hold up not just at initial approval, but years later when analysts, equipment, sites, or products have changed.
Organizations that treat lifecycle management as a documentation exercise typically struggle when performance drift, transfer failures, or investigations force decisions the original validation package never anticipated. This session focuses on building the operational and scientific judgment needed to manage that reality under ICH Q14 and Q2(R2) expectations.
Meredith Crabtree has over 30 years' experience in regulated industries, ranging from Blood, Plasma, Tissue, Laboratory, Pharma, Medical Device, Cosmetics, Supplements, and Animal Health. This includes manufacturing, packaging, labelling and distribution operations.
Meredith is the owner of MLKC Consulting, a Quality Consultant specializing in product label reviews, 3rd party inspections, Consent Decree and Recall support. She also performs regulatory assessments and Quality trainings.
Join Meredith Crabtree for this 90-minute session on analytical lifecycle management under ICH Q14 and Q2(R2) — and what it changes operationally.